Details Cookies
United Kingdom
Important margin product information

CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 73% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs, FX or any of our other products work and whether you can afford to take the high risk of losing your money.

Cookie policy

This website uses cookies to offer you a better browsing experience by enabling, optimising and analysing site operations, as well as to provide personalised ad content and allow you to connect to social media. By choosing “Accept all” you consent to the use of cookies and the related processing of personal data. Select “Manage consent” to manage your consent preferences. You can change your preferences or retract your consent at any time via the cookie policy page. Please view our cookie policy here and our privacy policy here

COVID-19 Vaccine: What is the timeline ? COVID-19 Vaccine: What is the timeline ? COVID-19 Vaccine: What is the timeline ?

COVID-19 Vaccine: What is the timeline ?

Christopher Dembik

Head of Macro Analysis

Summary:  There are good reasons for investors to wear rose-colored glasses right now. While economic risks remain elevated due to the wave of bankruptcies that is in sight, market optimism is rightly fueled by positive vaccine news and expectations of further monetary stimulus from the Federal Reserve and the European Central Bank as early as this month. With the United Kingdom being the first country to grant emergency approval to Pfizer's coronavirus vaccine, we publish today an update on a timeline for when a vaccine might be available for the rest of the world.

UK gives vaccine go ahead - This morning, the United Kingdom has approved for use the Pfizer/Biontech Covid-19 vaccine, opening the door to the start of the vaccination campaign early next week. This is the first country to authorize a vaccine using mRNA technology (which is a new type of vaccine that transfers molecules of synthetic RNA into human cells, as opposed to DNA vaccines). The regulatory approval is still pending for the Pfizer vaccine in the European Union and the United States. The approval date is anticipated to be on 10 December in the United States when the FDA committee is due to meet to assess quality and safety of the new vaccine while it may takes a bit longer in the European Union, perhaps one or two more weeks. According to various European sources, it is expected that the European Medicines Agency will provide an opinion on conditional marketing authorization by 29 December, thereby allowing the vaccination campaign to start at some point in January next year.

Distribution information in the UK – As it is the case in other European countries, the United Kingdom will not make the vaccines mandatory and there will be no introduction of “vaccine passports” enabling holders to travel and move freely. The vaccination campaign will be in nine steps, first targeting residents in a care home for older adults and their carers, all those 80 years of age and over and frontline health and social care workers. For each individual, the vaccination process consists of a 2-dose schedule, with protection against COVID-19 being achieved 28 days after the initiation of the vaccination. Given that the United Kingdom is about to start the vaccination campaign next week, it is likely that herd immunity will be reached at the end of Q1 2021 and that almost all the population will be vaccinated by the end of Q2 2021. A new lockdown is therefore unlikely to happen next year, but the tier system (three-tier rules in England and five-tier system in Scotland) and other restrictions measures that have been recently enacted should remain in place, at least until herd immunity is achieved.

France secures 100M doses of vaccine – The French government indicated today that it has secured around 100M doses of vaccine from seven suppliers. It would make it possible to vaccinate around 50M people (over a population of 67M people), with each individual being given two doses of the vaccine. The initial plan, which is subject to change as it is widely criticized among population, is to vaccinate around 35 to 40M individuals in 2021 and the rest of the population in 2022. If confirmed, it is a very slow timeline response to the crisis. Most other developed countries seek to vaccinate almost all the population at some point next year. The first deliveries should come in mid-January, initially from AstraZeneca (around 4.4M doses) and Pfizer (3.5M doses). Other suppliers, such as Moderna, are expected to start delivery in next February.

Below, you can see the timeline for when vaccine might be available in the following countries: Australia, the EU, Japan and the USA. Based on current scenario, immunization in developed countries will happen at the latest in the third quarter, putting a definitive end to the health crisis, though economic scars might remain longer.


Estimated doses for herd immunity (around 60% of the population)

Total doses available from various suppliers

Approval date of first vaccine

Vaccination of a large part of the population




In Q1 2021

Q2-Q3 2021

European Union



End of Dec (Pfizer)

Q3 2021




In Q1 2021

End of Q2 2021

United Kingdom



2 Dec (Pfizer)

End of Q2 2021

United States



10 Dec (Pfizer)

End of Q2 2021

Sources: European Commission, UK Department of Health and Social Care, U.S. HHS, Australian Government Department of Health, Japanese Ministry of Health, Labour and Welfare.


The Saxo Bank Group entities each provide execution-only service and access to Analysis permitting a person to view and/or use content available on or via the website. This content is not intended to and does not change or expand on the execution-only service. Such access and use are at all times subject to (i) The Terms of Use; (ii) Full Disclaimer; (iii) The Risk Warning; (iv) the Rules of Engagement and (v) Notices applying to Saxo News & Research and/or its content in addition (where relevant) to the terms governing the use of hyperlinks on the website of a member of the Saxo Bank Group by which access to Saxo News & Research is gained. Such content is therefore provided as no more than information. In particular no advice is intended to be provided or to be relied on as provided nor endorsed by any Saxo Bank Group entity; nor is it to be construed as solicitation or an incentive provided to subscribe for or sell or purchase any financial instrument. All trading or investments you make must be pursuant to your own unprompted and informed self-directed decision. As such no Saxo Bank Group entity will have or be liable for any losses that you may sustain as a result of any investment decision made in reliance on information which is available on Saxo News & Research or as a result of the use of the Saxo News & Research. Orders given and trades effected are deemed intended to be given or effected for the account of the customer with the Saxo Bank Group entity operating in the jurisdiction in which the customer resides and/or with whom the customer opened and maintains his/her trading account. Saxo News & Research does not contain (and should not be construed as containing) financial, investment, tax or trading advice or advice of any sort offered, recommended or endorsed by Saxo Bank Group and should not be construed as a record of our trading prices, or as an offer, incentive or solicitation for the subscription, sale or purchase in any financial instrument. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, would be considered as a marketing communication under relevant laws.

Please read our disclaimers:
- Notification on Non-Independent Investment Research (
- Full disclaimer (

Saxo Markets
40 Bank Street, 26th floor
E14 5DA
United Kingdom

Support Centre
For existing clients, please click here to request support via the Support Centre.

Have a question about our products, platforms or services? Visit the Support Centre to find answers for our most frequently asked questions. If you are still unable to locate an answer to your question, you will also find contact details for your local Saxo office to speak with a representative.

Contact Saxo

Select region

United Kingdom
United Kingdom

Trade Responsibly
All trading carries risk. To help you understand the risks involved we have put together a series of Key Information Documents (KIDs) highlighting the risks and rewards related to each product. Read more
Additional Key Information Documents are available in our trading platform.

Saxo Markets is a registered Trading Name of Saxo Capital Markets UK Ltd (‘SCML’). SCML is authorised and regulated by the Financial Conduct Authority, Firm Reference Number 551422. Registered address: 26th Floor, 40 Bank Street, Canary Wharf, London E14 5DA. Company number 7413871.

This website, including the information and materials contained in it, are not directed at, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in the United States, Belgium or any other jurisdiction where such distribution, publication, availability or use would be contrary to applicable law or regulation.

It is important that you understand that with investments, your capital is at risk. Past performance is not a guide to future performance. It is your responsibility to ensure that you make an informed decision about whether or not to invest with us. If you are still unsure if investing is right for you, please seek independent advice. Saxo Markets assumes no liability for any loss sustained from trading in accordance with a recommendation.

Apple, iPad and iPhone are trademarks of Apple Inc., registered in the U.S. and other countries. App Store is a service mark of Apple Inc. Android is a trademark of Google Inc.